國家衛生研究院 NHRI:
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 954911      線上人數 : 602
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版

    子類別

    期刊論文 [328/331]
    圖書 [1/1]
    會議論文/會議摘要 [115/179]

    鄰近社群


    于重元 [19/19]
    劉柯俊 [85/98]
    劉滄梧 [119/125]
    劉界元(2003-2010) [3/3]
    夏和雄(1996-2012) [26/31]
    夏興國 [51/54]
    姜乃榕 [82/94]
    常慧如 [39/44]
    張俊彥 [234/254]
    張光裕 [69/79]
    張憶壽 [104/107]
    張文祥 [52/53]
    張書銘 [89/91]
    彭汪嘉康(1996-2007) [120/126]
    施能耀 [37/43]
    李家惠 [29/29]
    李岳倫 [48/49]
    林素芳 [32/32]
    楊奕馨 [41/42]
    江士昇 [88/90]
    沈哲宏 [14/16]
    洪文俊 [88/88]
    莊雙恩 [82/91]
    蔡坤志 [32/34]
    蔡慧珍 [67/72]
    蘇勇曄 [40/40]
    蘇振良 [24/25]
    郭靜娟 [71/76]
    陳尚鴻 [45/48]
    陳振陽 [72/72]
    陳美霞(2002-2009) [1/1]
    陳詩政 [2/2]
    陳雅雯 [38/39]
    黃智興 [55/55]
    黃道揚 [26/26]
    丁兆治(2000-2004) [5/5]
    其他 [465/472]
    劉敏(1996-2007) [60/62]
    劉玫英(2004-2006) [2/2]
    吳成文(1996-2008) [53/55]
    曾思文(1997-2007) [4/4]
    李冠德(1997-2004) [4/6]
    林景太(1999-2007) [5/5]
    楊文光(1996-1999) [21/21]
    王全正(1996-2003) [4/4]
    莊聲宏(1997-2004) [11/11]
    詹宗晃(2000-2008) [2/2]
    賴基銘(2004-2008) [41/47]
    阮麗蓉(2000-2006) [6/7]
    陳俊叡(2003-2007) [6/6]
    馬彥英(1997-1999) [1/1]
    黃奇英(2005-2007) [9/10]

    社群統計


    近3年內發表的文件:75(14.68%)
    含全文筆數:444(86.89%)

    文件下載次數統計
    下載大於0次:444(100.00%)
    下載大於100次:426(95.95%)
    檔案下載總次數:178521(3.33%)

    最後更新時間: 2024-12-03 09:06

    上傳排行

    資料載入中.....

    下載排行

    資料載入中.....

    RSS Feed RSS Feed
    跳至:
    或輸入年份:
    由新到舊排序 由最舊的開始

    顯示項目176-200 / 511. (共21頁)
    << < 3 4 5 6 7 8 9 10 11 12 > >>
    每頁顯示[10|25|50]項目

    日期題名關聯
    2018-11 M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 153O.
    2018-10 Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P.
    2018-10 NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 733P.
    2018-10 The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P.
    2018-10 Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1 Annals of Oncology. 2018 Oct;29(Suppl. 8):250-251.
    2018-10 M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 757P.
    2018-10 Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 626PD.
    2018-09 Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials Oncology Research and Treatment. 2018 Sep;41(Suppl. 4):285-286.
    2018-08-24 BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor Cancer Science. 2018 Nov;109(11):3591-3601.
    2018-07 The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients Journal of the Chinese Medical Association. 2018 Jul;81(7):593-598.
    2018-06 Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma Annals of Oncology. 2018 Jun;29(6):1402-1408.
    2018-06 The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-152.
    2018-06 Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-153.
    2018-06 Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-150.
    2018-06 Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract O-004.
    2018-06 Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-151.
    2018-05 Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Abstract number e15127.
    2018-05 A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers Journal of Clinical Oncology. 2018 May;36(15, Suppl. S):Meeting Abstract 2556.
    2018-05 A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Meeting Abstract e16204.
    2018-04 The role of consolidation chemoradiotherapy in Locally Advanced Pancreatic Cancer receiving chemotherapy: An updated systematic review and meta-analysis Cancer Research and Treatment. 2018 Apr;50(2):562-574.
    2018-04 Dialysis increases the risk of bladder recurrence in patients with Upper Tract Urothelial Cancer: A population-based study Annals of Surgical Oncology. 2018 Apr;25(4):1086-1093.
    2018-03 Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use Kaohsiung Journal of Medical Sciences. 2018 Mar;34(3):181-183.
    2018-03 Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy Journal of Cancer Research and Practice. 2018 Mar;5(1):27-31.
    2018-02-01 Myeloid-derived macrophages and secreted HSP90alpha induce pancreatic ductal adenocarcinoma development OncoImmunology. 2018 Feb 1;7(5):Article number e1424612.
    2018-02 Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 460.

    顯示項目176-200 / 511. (共21頁)
    << < 3 4 5 6 7 8 9 10 11 12 > >>
    每頁顯示[10|25|50]項目

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋